US Stock MarketDetailed Quotes
ANAB AnaptysBio
- 23.410
- -2.820-10.75%
Close May 10 16:00 ET
- 23.410
- 0.0000.00%
Post 16:01 ET
639.53MMarket Cap-3812P/E (TTM)
26.140High23.230Low325.46KVolume26.140Open26.230Pre Close7.82MTurnover2.42%Turnover RatioLossP/E (Static)27.32MShares27.50052wk High13.38P/B314.69MFloat Cap13.36052wk Low--Dividend TTM13.44MShs Float134.000Historical High--Div YieldTTM11.09%Amplitude10.000Historical Low24.016Avg Price1Lot Size
AnaptysBio Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -64.15%-120.8M | -221.47%-34.35M | -105.52%-36.47M | -5.23%-25.41M | -16.91%-24.57M | -60.26%-73.59M | 57.77%-10.69M | -153.31%-17.75M | -351.77%-24.15M | 9.44%-21.01M |
| Net income from continuing operations | -27.11%-163.62M | -59.81%-42.21M | -11.36%-37.31M | -22.40%-39.85M | -22.07%-44.26M | -122.72%-128.72M | 18.82%-26.41M | -402.58%-33.5M | -7,488.34%-32.55M | -99.61%-36.26M |
| Depreciation and amortization | 1.76%2.38M | -0.33%604K | 1.20%592K | 2.80%587K | 3.49%593K | 11.72%2.34M | 57.40%606K | -12.56%585K | -27.26%571K | 128.29%573K |
| Other non cash items | -14.33%18.08M | 16.63%4.96M | -27.78%4.43M | -25.73%4.36M | -10.67%4.34M | 1,355.72%21.11M | --4.25M | --6.14M | --5.87M | --4.85M |
| Change In working capital | -104.74%-324K | -144.97%-2.66M | -353.75%-9M | 171.69%3.25M | 323.29%8.09M | 191.32%6.84M | 346.30%5.91M | 165.01%3.55M | -183.58%-4.53M | 121.78%1.91M |
| -Change in receivables | -900.37%-5.43M | -1,398.74%-3.58M | 40.82%-87K | -1,381.25%-1.66M | -131.11%-104K | 38.01%-543K | -107.83%-239K | -23.53%-147K | -118.51%-112K | 96.39%-45K |
| -Change in prepaid assets | -415.87%-4.19M | 66.74%2.84M | -305.46%-5.8M | 68.63%-1.29M | 104.18%51K | 54.86%-813K | -74.70%1.71M | 153.17%2.82M | -394.36%-4.12M | 49.17%-1.22M |
| -Change in payables and accrued expense | 12.76%10.94M | -131.00%-1.5M | -314.96%-2.7M | 8,706.67%6.61M | 141.32%8.53M | 304.64%9.7M | 190.81%4.83M | 758.12%1.26M | -98.70%75K | 171.00%3.54M |
| -Change in other current liabilities | -8.70%-1.64M | -7.97%-420K | -9.14%-418K | -8.82%-407K | -8.91%-391K | -1,990.28%-1.51M | -2,045.00%-389K | -342.41%-383K | -256.19%-374K | -147.59%-359K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -64.15%-120.8M | -221.47%-34.35M | -105.52%-36.47M | -5.23%-25.41M | -16.91%-24.57M | -60.26%-73.59M | 57.77%-10.69M | -153.31%-17.75M | -351.77%-24.15M | 9.44%-21.01M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 136.66%144.75M | 128.77%49.18M | 194.45%30.64M | 71.19%-20.46M | 127.29%85.4M | -1,116.72%-394.85M | 132.23%21.5M | -399.23%-32.43M | -287.02%-71M | -651.59%-312.91M |
| Net PPE purchase and sale | -125.42%-807K | -60.00%-280K | -224.00%-162K | -143.59%-190K | -218.18%-175K | 73.50%-358K | -1,150.00%-175K | 68.15%-50K | 90.96%-78K | 82.65%-55K |
| Net investment purchase and sale | 136.90%145.56M | 128.21%49.46M | 195.10%30.8M | 71.42%-20.27M | 127.35%85.57M | -1,081.65%-394.49M | 132.50%21.67M | -394.51%-32.38M | -282.67%-70.92M | -648.43%-312.86M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 136.66%144.75M | 128.77%49.18M | 194.45%30.64M | 71.19%-20.46M | 127.29%85.4M | -1,116.72%-394.85M | 132.23%21.5M | -399.23%-32.43M | -287.02%-71M | -651.59%-312.91M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -234.71%-59.3M | -364.70%-5.16M | -108.30%-3.07M | -3,223.15%-13.49M | -915.23%-37.57M | -82.55%44.02M | -99.22%1.95M | 15,263.90%37.03M | -22.02%432K | 2,659.88%4.61M |
| Net common stock issuance | -501.86%-47.53M | -92.28%264K | -94.07%160K | -1,451.56%-11.69M | -848.58%-36.26M | 363.26%11.83M | 114.90%3.42M | 1,019.92%2.7M | 56.14%865K | 2,800.60%4.84M |
| Net other financing activities | -136.56%-11.77M | -268.91%-5.42M | -109.42%-3.23M | -315.94%-1.8M | -458.72%-1.31M | -87.11%32.19M | ---1.47M | --34.33M | ---433K | ---235K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -234.71%-59.3M | -364.70%-5.16M | -108.30%-3.07M | -3,223.15%-13.49M | -915.23%-37.57M | -82.55%44.02M | -99.22%1.95M | 15,263.90%37.03M | -22.02%432K | 2,659.88%4.61M |
| Net cash flow | ||||||||||
| Beginning cash position | -85.62%71.31M | -55.09%26.3M | -50.90%35.21M | -43.18%94.56M | -85.62%71.31M | 97.88%495.73M | -82.60%58.55M | -78.42%71.7M | -41.45%166.41M | 97.88%495.73M |
| Current changes in cash | 91.67%-35.34M | -24.22%9.67M | 32.26%-8.91M | 37.33%-59.36M | 107.06%23.25M | -273.08%-424.42M | -91.99%12.76M | -422.88%-13.15M | -296.88%-94.71M | -1,077.43%-329.32M |
| End cash Position | -49.56%35.97M | -49.56%35.97M | -55.09%26.3M | -50.90%35.21M | -43.18%94.56M | -85.62%71.31M | -85.62%71.31M | -82.60%58.55M | -78.42%71.7M | -41.45%166.41M |
| Free cash flow | -64.44%-121.61M | -218.87%-34.63M | -105.85%-36.64M | -5.67%-25.6M | -17.44%-24.74M | -56.39%-73.95M | 57.10%-10.86M | -147.94%-17.8M | -377.55%-24.23M | 10.42%-21.07M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg